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Abstract
Objective: There is emerging evidence from animal studies suggesting a key role for methylation in the pathogenesis of
essential hypertension. However, to date, very few studies have investigated the role of methylation in the development of
human hypertension, and none has taken a genome-wide approach. Based on the recent studies that highlight the
involvement of inflammation in the development of hypertension, we hypothesize that changes in DNA methylation of
leukocytes are involved in the pathogenesis of hypertension.
Method & Results: We conducted a genome-wide methylation analysis on 8 hypertensive cases and 8 normotensive age-
matched controls aged 14–23 years and performed validation of the most significant CpG sites in 2 genes in an
independent sample of 36 hypertensive cases and 60 normotensive controls aged 14–30 years. Validation of the CpG sites in
the SULF1 gene was further conducted in a second replication sample of 36 hypertensive cases and 34 controls aged 15.8–
40 years. A CpG site in the SULF1 gene showed higher methylation levels in cases than in healthy controls in the genome-
wide step (p = 6.261025), which was confirmed in the validation step (p = 0.011) for subjects #30 years old but was not
significant for subjects of all ages combined (p = 0.095).
Conclusion: The identification of a difference in a blood leukocyte DNA methylation site between hypertensive cases and
normotensive controls suggests that changes in DNA methylation may play an important role in the pathogenesis of
hypertension. The age dependency of the effect further suggests complexity of epigenetic regulation in this age-related
disease.
Citation:Wang X, Falkner B, Zhu H, Shi H, Su S, et al. (2013) A Genome-Wide Methylation Study on Essential Hypertension in Young African American Males. PLoS
ONE 8(1): e53938. doi:10.1371/journal.pone.0053938
Editor: Brock C. Christensen, Geisel School of Medicine at Dartmouth, United States of America
Received September 13, 2012; Accepted December 4, 2012; Published January 10, 2013
Copyright:  2013 Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The participants in this study were recruited by several National Institutes of Health funded projects including HL69999, HL56622, HL077230, HL64157,
DK046107 & HL092030. The current study is funded by the NLHBI HL105689. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: xwang@georgiahealth.edu
Introduction
Essential hypertension (EH) is a major health problem
worldwide with approximately one in three adults suffering from
the disease. Although twin and family studies highlight a clear
inherited component to EH [1], the current purely sequence-based
approach only accounts for a fraction of the genetic risk of the
disease as evidenced by the recent genome-wide association studies
in which the identified genetic variants explain less than 1% of the
blood pressure (BP) variation in the population [2]. Several
epidemiological and clinical peculiarities of EH such as the
incomplete concordance between monozygotic (MZ) twins (ranges
from 38% to 52%) [3,4] and its late onset and progressive nature,
are difficult to explain with traditional DNA sequence-based
approaches. These observations may indicate the involvement of
epigenetic factors in EH development. Epigenetics refers to all
meiotically and mitotically heritable changes in gene expression
that are not coded in the DNA sequence itself. DNA methylation is
an important epigenetic modification and can play a significant
regulatory role in both normal and pathological cellular processes.
Emerging evidence from animal studies [5,6,7,8] suggests a key
role for methylation in the pathogenesis of EH. However, to date,
very few studies [9,10] have investigated the role of methylation in
the development of human EH, and none has taken a genome-
wide approach. Based on recent studies [11,12] that highlight the
involvement of inflammation in the development of EH, we
hypothesized that changes in the DNA methylation of leukocytes
are involved in the pathogenesis of EH. The goal of this study was
to characterize the DNA methylation profile in peripheral blood
leukocytes in EH cases versus normotensive controls using a 3-
stage genome-wide approach.
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Methods
Subjects
A total of 44 EH cases and 68 age (62 years) matched controls
were selected from 4 existing cohorts in Georgia Prevention
Institute, Georgia Health Sciences University using the following
inclusion criteria: (1) African American (AA) ancestry; (2) male; (3)
having leukocyte DNA available; (4) EH cases have age, sex, and
height adjusted systolic BP (SBP) $95th percentile (if the age of the
subject is less than 20 years), or SBP$140 mmHg, while controls
have age, sex and height adjusted SBP#20th percentile, or have
SBP levels,120 mmHg. These 4 cohorts include the BP stress
study (n= 603) [13], the Georgia Cardiovascular twin study
(n = 1183) [14], the Lifestyle, Adiposity, and Cardiovascular
Health in Youth (LACHY) study (n = 740) [15], and the Pre-
vention of Hypertension in African American Teens (PHAT) study
(n = 262) [16]. Both the BP Stress study and the twin study are on-
going longitudinal studies which have followed the subjects for
more than 10 years. Both studies included roughly equal numbers
of AAs and European Americans (EA) or males and females. The
BP stress study was established in 1989 with subjects aged 7–16
years at baseline [13] and the Georgia Cardiovascular Twin study
was established in 1996 with subjects aged 7–25 years at baseline
[14]. LACHY and PHAT are cross-sectional studies. The LACHY
study [15]consisted of roughly equal numbers of AA and EA
adolescents aged 14–18 years of both sexes and the PHAT study
[16] consisted of AA males and females aged 14–20 years. For the
subjects from the BP Stress and the Georgia Cardiovascular Twin
study, if multiple visits (with multiple leukocyte DNA) were
available for a subject, the leukocyte DNA collected at the visit
when the subject had the highest (for cases) or lowest (for controls)
SBP was used. For the subjects from the twin study, only one twin
from a pair was selected if both twin and co-twin met the criteria.
Subjects in all the 4 studies were recruited from Augusta, GA
area. For all four cohorts self identification by self-reports of each
subject or by a parent if the subject was under 18 years of age was
used to classify ethnicity according to previously described criteria
[17]. Subjects in all the 4 studies were overtly healthy, free of any
acute or chronic illness on the basis of parental reports and were
not on anti-hypertensive, lipid lowering, anti-diabetic and anti-
inflammatory medications [13,14,15,16]. The Institutional Review
Board at the Medical College of Georgia approved the studies.
Written informed consent was obtained from all subjects and by
parents if subjects were younger than 18 years of age.
The discovery panel included 7 EH cases and 7 age matched
controls selected from the 44 EH cases and 68 controls from the
Georgia cohorts. To increase the power, we also included 1 AA
male MZ pair discordant for EH selected from the Georgia CV
twin study in which the EH case had age, sex, and height adjusted
SBP$95th percentile while the control had SBP levels 20 mmHg
less than the case.
We included the remaining 37 cases and 61 controls not used in
the discovery panel into the first replication panel. However, one
EH case and one control failed the pyrosequencing assay. In total,
the first replication stage included 36 cases and 60 controls.
The subjects in the second replication panel were selected from
two existing cohorts at Thomas Jefferson University, Philadelphia,
Pennsylvania. The first cohort included 412 young AA adults aged
18–49 years [18] and the second cohort included 300 AA youth
aged 12–19 years [19]. A total of 38 AA male cases
(SBP$140 mmHg or DBP$90 mmHg with or without medica-
tion) and 38 age (62 years) and BMI (normal/overweight/obese)
matched male controls (SBP,120 mmHg and DBP,80 mmHg)
were selected from the young adult cohort and 6 AA male EH
cases (SBP$140 mmHg) and 6 age (62 years) and BMI (normal/
overweight/obese) matched controls (SBP,110 mmHg and
DBP,70 mmHg) were selected from the youth cohort. Four
more controls from the young adult cohort were further included
to increase the overall number to 92, which is the number of
samples that can be measured by pyrosequencing in one plate.
Unfortunately, 22 subjects turned out to have insufficient DNA
available to conduct the pyrosequencing. That is, in this 2nd
replication cohort data were only available in 70 subjects (63 from
the young adult cohort and 7 from the youth cohort).
The participants in both the young adult cohort and the youth
cohort were living in urban Philadelphia. All protocols were
approved by the Institutional Review Board of Thomas Jefferson
University and written informed consent was obtained from each
participant at enrollment or from parents if subjects were less than
18 years of age. The participants in the youth cohort were overtly
healthy, free of any acute or chronic illness on the basis of parental
reports and were not on anti-hypertensive, lipid lowering, anti-
diabetic and anti-inflammatory medications. For the young adult
cohort, the exclusion criteria included secondary HBP, history of
diabetes, renal disease, heart failure, autoimmune disease, sickle
cell anemia, or endocrine disorders.
Measurements
For all the four Georgia cohorts, height and weight were
measured by standard methods using a wall-mounted stadiometer
and a scale, respectively. Body mass index (BMI) was calculated as
weight/height2. SBP and diastolic BP (DBP) were measured with
Dinamap monitors, using an appropriately sized BP cuff placed on
the subject’s right arm. BP measurements were taken at 11, 13,
and 15 minutes, during a 15-minute supine relaxation period. The
average of the last 2 readings was used to represent SBP and DBP
values [13,14,15,16].
Fasting peripheral blood samples in the LACHY cohort and
non-fasting peripheral blood samples in the other three cohorts
were collected. The buffy coat and plasma samples were separated
and stored at 280uC. DNA was extracted from the buffy coat.
For the two cohorts in Pennsylvania, BP was measured, in the
seated position, by auscultation. The average of eight separate BP
measurements obtained at two separate visits (four measurements
at each visit) was used to represent BP values. Fasting peripheral
blood samples were collected and DNA was extracted from the
buffy coat [18,19].
Genome-wide Methylation Chip
The HumanMethylation27 BeadChip from Illumina (Illumina,
San Diego, CA, USA) was used. This chip can quantitatively
measure 27, 000 CpG sites, covering more than 14,000 well-
annotated genes at single-CpG resolution. Each chip can
accommodate 12 samples. After bisulfite treatment, 200 ng of
the converted DNA was whole genome amplified (WGA) and
enzymatically fragmented. The bisulfite-converted WGA-DNA
samples were purified and applied to the BeadChips. Image
processing and intensity data extraction were performed according
to Illumina’s instructions (www.illumina.com/products/
infinium_humanmethylation27_beadchip_kits.ilmn). Each meth-
ylation data point is represented by fluorescent signals from the
methylated and unmethylated alleles. DNA methylation beta
values are continuous variables between 0 (completely unmethy-
lated) and 1 (completely methylated), representing the ratio of the
intensity of the methylated bead type to the combined locus
intensity. Initial array processing and quality control were
performed with BeadStudio software. The microarray data
discussed in this paper have been deposited in NCBI’s Gene
Genome Wide Methylation Study on Hypertension
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Expression Omnibus and are accessible through GEO Series
accession number GSE42774.
Pyrosequencing
The methylation levels of the top CpG sites from the 2 genes
selected for replication were determined by pyrosequencing
technology, a rapid and robust method for quantitative methyl-
ation analysis. After bisulfite treatment, 10 ng of the converted
DNA was used in a PCR reaction to amplify the target region.
One of the PCR primers was biotin labeled. Single-stranded
biotinylated PCR products were prepared for sequencing by use of
the Pyrosequencing Vacuum Prep Tool according to the
manufacturer’s instructions. The PCR products (each 10 ml) were
sequenced by Pyrosequencing PSQ96 HS System (Pyrosequen-
cing-Qiagen) following the manufacturer’s instructions. The
methylation status of each locus was analyzed individually as
a T/C SNP using QCpG software (Biotage, Kungsgatan,
Sweden). PCR primers and sequencing primers for the 2 genes
selected for replication are available upon request.
Statistical Analysis
To identify genome wide methylation differences between EH
cases and controls, the LIMMA (Linear Models for Microarray
Analysis) package from the Bioconductor project [20] was used.
LIMMA uses an empirical Bayes approach that uses the
variability in all genes for testing for significant differences,
which results in more stable inferences for a relatively small
number of arrays. We used a design matrix of a paired test to
analyze each CpG site for differential methylation. Each CpG
site was assigned a raw p-value based on a moderated t statistic.
To correct for multiple testing, the set of raw p-values were
converted to false discovery rates (FDR) according to Benjamini
and Hochberg [21]. For the replication cohort, the methylation
levels of the CpG sites were square root-transformed to obtain
a better approximation of the normal distribution prior to
analysis. A Student’s t-test was used to investigate whether their
methylation levels differed between cases and controls. Linear
regression was further used to adjust for the potential effect of
age and BMI. We combined the replication steps as well as the
genome wide step on the CpG sites carried to the validation
stages with meta-analysis using the weighted z score–based
approach implemented in the package METAL [22]. Pre-
liminary analyses, t-tests and regression analyses were done
using STATA 8 (StataCorp, College Station, Texas).
Gene ontology analysis was conducted with the FatiGO tool
[23]. FatiGO takes two lists of genes and converts them into
two lists of GO terms. Then a Fisher’s exact test for 262
contingency tables is used to check for significant over-
representation of GO terms in one of the sets with respect to
the other one. Multiple testing correction (indexed by adjusted p
values) to account for the multiple hypotheses tested (one for
each GO term) was applied to reduce the likelihood of false
positives. Since at least two CpG sites were included for the
majority of genes in the genome-wide chip, for each gene we
only used the CpG site with the lowest p value.
Results
Table 1 displays the general characteristics of the 7 EH cases
and 7 controls in the discovery panel and Table S1 displays the
general characteristics of the 1 MZ pair discordant for EH.
Figure 1 is a volcano plot showing the raw p-values for all CpG
sites versus mean methylation difference between the case and the
control group. We did not observe any CpG sites survive multiple
testing corrections with the most significant CpG site showing
a FDR of 0.75 and a raw p value of 6.261025. Table 2 lists the top
10 most significant CpG sites. Out of the 10 CpG sites, we selected
the top 2 CpG sites (one CpG site in the sulfatase 1 gene [SULF1]
and one CpG site in the prolylcarboxypeptidase gene [PRCP]) for
validation in the replication cohort. The general characteristics of
the first replication cohort are displayed in Table 3. Although the
pyrosequencing assays were designed to target one specific CpG
site for each gene (Illumina ID cg04845579 for SULF1 and
cg09772827 for PRCP), both assays covered several surrounding
CpG sites. For the SULF1 gene, methylation levels on 4 CpG sites
were obtained with CpG2 as the target CpG site. All these 4 CpG
sites locate in the promoter region with a distance of 214, 186,
119, and 99 base pairs upstream to the transcription starting site.
The differences in methylation status of these 4 CpG sites between
cases and controls are shown in Table 4. The methylation levels of
CpG1 and CpG2 (the target CpG site) were significantly higher in
cases than in controls (p = 0.040 and 0.046, respectively). The
results remained significant after adjustment for age (p= 0.041 and
0.038, respectively) but became non-significant after further
adjustment for BMI (p= 0.074 and 0.081, respectively). For the
PRCP gene, methylation levels on 8 CpG sites were obtained with
CpG6 as the target CpG site. All these 8 CpG sites locate in the
first intron with a distance of 293, 302, 305, 320, 323, 346, 353
and 365 base pairs downstream of the transcription starting site.
The differences in methylation status of these 8 CpG sites between
cases and controls are shown in Table S2. None of these CpG sites
showed a significant difference in their methylation levels between
cases and controls (p ranged from 0.22–0.87). The correlations
within samples among the multiple CpG sites measured within
each of these two genes are listed in Tables S3 and S4,
respectively.
The CpG sites in the SULF1 gene were further validated in the
second replication panel. The general characteristics of this cohort
are displayed in Table 5. To keep the second comparable to the
first replication which only comprised subjects #30 years old, we
further split the sample by age (#30 years or .30 years). The
general characteristics of the split samples were also listed in
Table 5. The differences in methylation status of these 4 CpG sites
in the SULF1 gene between cases and controls in the second
replication panel are shown in Table 6. None of these 4 CpG sites
showed a significant difference in their methylation levels between
cases and controls either in the overall sample or in the samples
split by age. Meta-analysis on the CpG1 and CpG2 with the two
replication panels was conducted and the results are shown in
Table 7. Significant higher methylation levels of CpG1 & CpG2
were observed in cases (p = 0.014 and p= 0.011, respectively) in
the meta-analysis on the first replication cohort and the young age
group of the second replication cohort. The significant result
remained after adjustment of age (p= 0.017 and p= 0.015,
respectively) or age and BMI (p= 0.030 and p= 0.037, re-
spectively). Further meta-analysis with the discovery panel on
CpG2 showed a p value of 0.0051 (with p= 0.0027 after
adjustment of age and p= 0.0171 after adjustment of age and
BMI) in all the subjects and a p value of 0.0004 (with p= 0.0004
after adjustment of age and p= 0.0054 after adjustment of age and
BMI) in subjects younger or equal to 30 years old.
Gene Ontology analysis was performed to test whether some
common functional trends in molecular functions and biological
processes were associated with the genes exhibiting differences
between cases and controls for the genome-wide methylation
analyses. We included those genes with a raw p#0.01 in the first
list (n = 226) and included all the other genes in the second list. As
expected from a pilot study in 8 cases and 8 controls, we did not
Genome Wide Methylation Study on Hypertension
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observe any GO categories survive multiple testing. Table S5 list
the GO categories with raw P value less than 0.05. Interestingly,
we observed enriched functional processes that are potentially
relevant for inflammation with response to biotic stimulus
(GO:0009607), response to other organism (GO:0051707), in-
terleukin-1 production (GO:0032612), and interleukin-13 pro-
duction (GO:0032616) among the top GO categories. The results
are consistent with the involvement of inflammation and oxidative
stress in the development of EH.
Discussion
In this study we aimed to identify methylation differences in
peripheral blood leukocytes between EH cases and controls using
a genome-wide approach in male AA youth and young adults. We
observed increased methylation levels at two CpG sites in the
SULF1 gene in EH cases in comparison with normotensive
controls in subjects equal or younger than 30 years.
Our study is the first genome wide methylation study on EH. In
fact, there are very few human studies that explored the role of
epigenetics on the risk of EH. In one study, Friso et al [9]
measured promoter methylation of the HSD11B2 gene in
peripheral blood mononuclear cells from patients with EH and
32 subjects on prednisone therapy. Elevated HSD11B2 promoter
methylation was associated with decreased HSD11B2 activity and
EH development in glucocorticoid-treated patients. In a recent
study by Smolarek et al [10] global DNA methylation level
indexed by the genome level of 5-methylcytosine was significantly
lower in patients with EH in comparison with controls.
The protein encoded by the SULF1 gene is Sulfatase 1 (Sulf1). It
is a cell surface polypeptide that can rapidly modify the sulfation
status of heparin sulfate proteoglycans (HSPGs), resulting in
changes in HSPG-related signal transduction pathways [24]. Sulf1
has been reported to be down-regulated in several human cancers
[25,26]. Absence of Sulf1 in cancer cell lines is associated with
increased cell growth, proliferation and reduced cell apoptosis
[25]. In addition to cancer, Sulf1 was also studied with respect to
normal development including neural, muscular, vascular and
skeletal development. However, there is no direct study on Sulf1
Figure 1. Volcano plot showing raw p values versus mean methylation difference between cases and controls. The two most
significant CpG sites are highlighted in red.
doi:10.1371/journal.pone.0053938.g001




Age, years 18.063.1 [14.8–23.3] 18.363.2 [14.8–23.0]
BMI, kg/m2 27.363.5 [21.2–31.5] 23.865.5 [17.8–33.2]
SBP, mmHg 145.864.7 [137.3–149.5] 107.663.3 [103.3–114]
SBP percentile 0.9960.01 [0.96–1.0] 0.1660.04 [0.10–0.19]
DBP, mmHg 69.166.8 [62.0–78.3] 55.465.4 [49.5–63.3]
DBP percentile 0.4560.22 [0.25–0.89] 0.1460.10 [0.01–0.26]
Means6SD [Range].
doi:10.1371/journal.pone.0053938.t001
Genome Wide Methylation Study on Hypertension
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and EH. SULF1 and SULF2 (another protein in this family) double
knockout mice show impairment in skeletal development [27], but
whether they display high blood pressure has never been explored.
In this study, we observed that the methylation levels of 2 CpG
sites in the promoter region of the SULF1 gene were higher in EH
cases than in controls. This is in line with the previous studies
[28,29] in cancers in which epigenetic silencing is involved in the
down-regulation of Sulf1. The SULF1 gene spans a ,211 kb
genomic fragment on chromosome 8q13.3 with 23 exons [25].
Staub et al. [29] observed that methylation of 12 CpG sites within
SULF1 exon 1A was associated with ovarian cancer cells and
primary ovarian cancer tissues lacking Sulf1 expression. This
region is about 10 kb downstream of the promoter region we
targeted. The relationship between the methylation level of this
region and the promoter region is unknown. No CpG island exists
in this gene and the two CpG sites showing significant association
with EH in our study locate at a distance of 214bp and 186 bp
upstream from the transcription start site. There is a possibility
that methylation of these two CpG sites or other CpG sites with
methylation levels correlated with them inhibits the interactions
between DNA sequence and nuclear proteins, resulting in changes
in gene expression. In-silico analysis of the region of these two
CpG site using TFSEARCH software [30] did not find they
located at any known transcription factor binding sites. However,
methylation of these two CpG sites may suppress gene transcrip-
tion by recruiting methylcytosine-binding proteins that in turn
associate with large protein complexes containing corepressors and
histone deacetylases. The binding of these complexes to DNA may
lead to a change in the chromatin structure from an active to an
inactive form [31]. This speculation needs to be confirmed.
The age dependency of the effect of SULF1 gene methylation on
EH may be related to the different pathogenesis of EH in youth in
comparison with middle aged or older people. For examples,
sympathetic nervous system hyperactivity is most apparent in
youth with EH while abnormal development of aortic elasticity or
reduced development of the microvascular network is more related
to high BP later in life [32]. Furthermore, there is evidence
showing that BP regulation may be controlled by different set of
genes at different ages [1]. Two longitudinal twin studies [33,34]
have observed age-specific genetic variation for blood pressure,
this is, there are new genes being switched on or off at different
time points. On the other hand, it is also possible that the current
study did not have enough power to find the effect of methylation
on EH in middle aged or older people in consideration of the fact
that disease-specific epigenetic alterations may be masked by the
background of age-related and medication-arising epigenetic
‘‘drift’’ [35,36].
The observed DNA methylation differences between EH cases
and controls were relatively small. They were 6.7% in the genome-
wide step and 4.1% in the replication step for the SULF1 gene
CpG2. This modest level of differences raises an important
question: what is the biological significance of changes in
methylation to this degree? Although transcriptional profiling
studies will be very valuable in understanding this question,
Table 2. Top 10 differentially methylated CpG sites.
Gene Illumina ID Distance to TSS CpG island Methylation, % P FDR
Case Control Difference
SULF1 cg04845579 186 NO 29.49 22.79 6.70 0.000062 0.75
PRCP cg09772827 346 YES 13.85 17.87 24.03 0.000098 0.75
NEUROG1 cg14958635 – YES 7.82 11.24 23.41 0.000134 0.75
PITPNA cg11719157 630 YES 61.38 57.51 3.87 0.000182 0.75
SLC26A10 cg14371590 222 NO 22.04 27.33 25.30 0.000209 0.75
CDC34 cg27431859 691 YES 10.43 13.45 23.02 0.000315 0.75
C9orf95 cg07962315 1375 NO 37.50 42.83 25.33 0.000321 0.75
YWHAQ cg06701500 565 YES 13.79 20.26 26.47 0.000334 0.75
SIRT7 cg15118204 191 YES 19.48 21.89 22.41 0.000348 0.75
CLDN5 cg04463638 148 NO 75.20 72.27 2.93 0.000483 0.75
TSS, transcription starting site.
doi:10.1371/journal.pone.0053938.t002




Age, years 20.665.3 [14.3–30.7] 19.664.5 [14.1–30.9]
BMI, kg/m2 29.968.7 [21.0–52.4] 24.768.0 [16.5–59.9]
SBP, mmHg 143.667.5 [133.3–175] 106.965.2 [93.7–117]
SBP percentile 0.9860.01 [0.96–1.00] 0.1260.06 [0.02–0.20]
DBP, mmHg 71.9610.4 [56.5–96.5] 58.665.6 [46–74.5]
DBP percentile 0.5060.23 [0.18–0.98] 0.2060.13 [0.03–0.67]
Means6SD [Range].
doi:10.1371/journal.pone.0053938.t003
Table 4. Pyrosequencing results of SULF1 gene in GA cohort.
Case Control P P, adjusteda P, adjustedb
CpG1 16.869.0 13.467.5 0.040 0.041 0.074
CpG2 22.769.4 19.068.6 0.046 0.038 0.081
CpG3 5.9463.04 4.863.22 0.105 0.098 0.204
CpG4 20.669.1 17.867.9 0.106 0.101 0.238
aAdjusted for age.
bAdjusted for age and BMI.
doi:10.1371/journal.pone.0053938.t004
Genome Wide Methylation Study on Hypertension
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cellular RNA is not available for the samples used in the current
study, which were selected from several existing cohorts. We
searched the GEO database and identified a dataset [37]
(GSE3846) which included genome wide gene expression data in
peripheral blood samples in six healthy volunteers tested by
Affymetrix microarrays. In all the 6 samples, the expression of
SULF1 was detectable. The average expression value of SULF1 is
4.38 at baseline. The average rank order of expression measure-
ment in each subject is 69%, which means that about 31% genes
have lower gene expression levels compared with SULF1 in
peripheral blood samples of healthy individuals. This confirms that
the SULF1 gene is expressed in peripheral blood cells. However,
we failed to find any GEO dataset which included both
methylation and gene expression data from peripheral blood
samples. Therefore, we cannot test whether DNA methylation in
SULF1 affects its expression in peripheral blood cells.
In this study, we used the DNA from leukocytes, which
represent different cell populations with distinct epigenetic profiles
[38]. A recent study by Kelsey’s group [39] indicated that shifts in
leukocyte subpopulations may account for a considerable pro-
portion of variability in peripheral blood DNA methylation of
diseases such as head and neck squamous cell carcinoma and
ovarian cancer. This study also provided a list of the top 50
differentially methylated CpG sites among 6 leukocyte subtypes
including CD4+ T cells, CD8+ T cells, CD56+ NK cells, B cells,
monocytes and granulocytes. The SULF1 gene CpG site is not
within the list. Another study [40] from the same group developed
an algorithm which predicts the distributions of the 6 leukocyte
subtypes using illumina 27 k methylation data from peripheral
blood DNA. We applied this algorithm to our data and did not
observe difference in the distributions of these 6 cell types between
EH cases and controls (Table S6). Therefore, it is highly unlikely
that our significant finding on the SULF1 gene is caused by shifts in
these 6 leukocyte subpopulations. On the other hand, it is plausible
that only the change in the epigenetic profile of one specific cell
type is related to EH. In this case, the actual epigenetic differences
might be more substantial than reported here but only present in
this specific blood leukocyte cell type. Future studies on epigenetic
profiling of various types of cell populations of leukocytes are
warranted to gain a greater understanding of the epigenetic
dysregulation in EH.
Two strengths of our study deserve mentioning. First, we
selected controls with low blood pressure, which maximizes the
power to make discoveries. Second, a hypothesis free genome-wide
approach was used. This approach supersedes the limitations
Table 5. General characteristics of the subjects in PA cohort (2nd replication panel).
All subjects Subjects older than 30 Subjects younger or equal to 30
Case Control Case Control Case Control
N 36 34 31 25 5 9
Age, years 39.367.6 35.669.7 41.863.8 40.863.7 23.666.2 21.165.1
Age range, years 16.8–49 15.8–47 33–49 34–47 16.8–30 15.8–28
BMI, kg/m2 29.566.2 28.565.7 29.466.2 28.465.6 30.467.0 28.962.1
SBP, mmHg 149.5616.3 108.366.4 149.8617.4 108.166.7 147.665.6 109.062.0
DBP, mmHg 94.6612.3 68.166.1 96.8610.3 6966.1 80.9616.2 65.766.0
Antihypertensive
Medication
25% 0% 29% 0% 0% 0%
Means6SD.
doi:10.1371/journal.pone.0053938.t005
Table 6. Pyrosequencing results of SULF1 gene in the PA
cohort.
Case Control P P, adjusteda P, adjustedb
Overall
CpG1 12.566.2 12.165.6 0.77 0.61 0.65
CpG2 19.767.0 18.966.7 0.64 0.51 0.53
CpG3 5.362.1 5.661.9 0.59 0.77 0.69
CpG4 20.967.3 21.067.0 0.97 0.94 0.96
Older than30
CpG1 11.966.4 12.065.9 0.81 0.88 0.80
CpG2 19.167.3 18.667.3 0.85 0.81 0.86
CpG3 5.162.1 5.662.2 0.39 0.41 0.35
CpG4 20.367.3 21.167.9 0.70 0.70 0.66
Younger or equal to 30
CpG1 16.362.7 12.564.9 0.13 0.18 0.16
CpG2 23.663.3 19.764.6 0.12 0.20 0.25
CpG3 6.961.9 5.761.0 0.13 0.17 0.22
CpG4 24.966.4 20.864.2 0.17 0.23 0.21
aAdjusted for age.
bAdjusted for age and BMI.
doi:10.1371/journal.pone.0053938.t006
Table 7. Meta -analysis on two CpG sites in the SULF1 gene.
P P, adjusteda P, adjustedb
CpG1 GA cohort+PA cohort 0.080 0.059 0.098
GA cohort+PA cohort (age#30) 0.014 0.017 0.030
CpG2 GA cohort+PA cohort 0.095 0.058 0.105
GA cohort+PA cohort (age#30) 0.011 0.015 0.037
Discovery+Replication 0.0051 0.0027 0.0171
Discovery+Replication (age#30) 0.0004 0.0004 0.0054
aAdjusted for age.
bAdjusted for age and BMI.
doi:10.1371/journal.pone.0053938.t007
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imposed by candidate gene methylation studies and allows
searching the whole genome in an unbiased manner.
Interpretation of these data is also limited by several additional
constraints. First, in this study we aimed to identify EH related
methylation changes. However, our study design cannot de-
termine whether the identified methylation changes are the cause
or the consequence of EH. Future studies on subjects with baseline
DNA and follow-up for de novo development of EH will be needed
to resolve causality [41]. Second, because obesity is an important
risk factor for EH, patients often have higher BMI levels than
normotensive controls. Obesity might be a confounder explaining
the relation between methylation levels of the SULF1 gene and
EH. In the first replication cohort, the association of the SULF1
gene CpG1 and CpG2 with EH attenuated and became non-
significant after adjustment of BMI. Therefore, in the second
replication cohort, controls were selected to match with cases on
obesity status (normal weight/overweight/obese). We could not
replicate the findings from the first 2 stages in the overall analysis.
In addition to BMI, this discrepancy might also be due to the age
difference between the second replication cohort and the cohorts
used in the first 2 stages. Moreover, it is also possible that SULF1
gene methylation is a mediator of obesity related EH. In this case,
including BMI as a covariate in the analysis or matching cases and
controls on obesity status will lead to over-adjustment. Future
studies on hypertensive subjects with normal weight are needed to
clarify whether SULF1 gene methylation independently affects
EH. Third, in the current study, the Infinium HumanMethyla-
tion27 Beadchip was selected because of its quantitative measure
at each CpG site. However, the limited coverage of this genome-
wide chip will restrict the findings to certain CpG sites within
certain genes. Future studies should use chips with more complete
coverage of the genome such as the recently released 450 K
Infinium Methylation BeadChip from Illumina. Fourth, the
current study is a pilot study with the genome-wide step conducted
only in 7 EH cases and 7 normotensive controls and one MZ pair
discordant for EH. Future studies with much larger sample size are
warranted to discover a more complete profile of EH related
methylation changes.
In conclusion, we identified a reproducible change in DNA
methylation of peripheral blood leukocytes between EH cases and
controls in subjects #30 years. It provides preliminary evidence
that DNA methylation may play an important role in the
pathogenesis of EH. Further studies are warranted to determine
the causal direction of this relationship.
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